₹1,053 - That's What Analysts Think MedPlus Health Services Limited (NSE:MEDPLUS) Is Worth After These Results

As you might know, MedPlus Health Services Limited (NSE:MEDPLUS) recently reported its yearly numbers. MedPlus Health Services missed revenue estimates by 2.2%, coming in at₹61b, although statutory earnings per share (EPS) of ₹12.52 beat expectations, coming in 3.0% ahead of analyst estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the most recent consensus for MedPlus Health Services from five analysts is for revenues of ₹67.6b in 2026. If met, it would imply a decent 10% increase on its revenue over the past 12 months. Per-share earnings are expected to soar 38% to ₹17.31. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹71.6b and earnings per share (EPS) of ₹17.07 in 2026. The consensus seems maybe a little more pessimistic, trimming their revenue forecasts after the latest results even though there was no change to its EPS estimates.

Check out our latest analysis for MedPlus Health Services

The analysts have also increased their price target 9.7% to ₹1,053, clearly signalling that lower revenue forecasts next year are not expected to have a material impact on MedPlus Health Services' valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values MedPlus Health Services at ₹1,180 per share, while the most bearish prices it at ₹933. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that MedPlus Health Services' revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 10% growth on an annualised basis. This is compared to a historical growth rate of 17% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 6.8% per year. Even after the forecast slowdown in growth, it seems obvious that MedPlus Health Services is also expected to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also downgraded MedPlus Health Services' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. With that said, earnings are more important to the long-term value of the business. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for MedPlus Health Services going out to 2028, and you can see them free on our platform here.

We also provide an overview of the MedPlus Health Services Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.